Does Higher Quality of Care in Systemic Lupus Erythematosus Improve Quality of Life?
- PMID: 35792677
- DOI: 10.1002/acr.24979
Does Higher Quality of Care in Systemic Lupus Erythematosus Improve Quality of Life?
Abstract
Objective: To study the association between high quality of care (QOC) and quality of life (QOL) and nonroutine health care use (HCU) in systemic lupus erythematosus.
Methods: Data were derived from 814 participants from the Lupus Outcomes Study sample. Data on sociodemographic information, disease status, medications, and health care variables were collected through annual interviews. QOC was measured at baseline on 13 quality indices amenable to self-report. Follow-up QOL was measured using the Short Form 36 health survey (SF-36) 2 years later. Univariate and multivariate regression analyses assessed the relationship between QOC and SF-36 scores at baseline, and logistic regression analyses evaluated QOC at baseline as a predictor of minimal clinically important difference (MCID) improvements in SF-36 scores, emergency room (ER) visits, and hospitalizations at follow-up.
Results: Higher QOC was associated with worse scores on SF-36 domains on univariate analysis at baseline, which was mediated by comorbidities and high disease activity. QOC and the number of years in high QOC were not predictive of MCID improvements in SF-36 scores at follow-up, which were driven by baseline SF-36 scores, disease activity, and nonroutine HCU. A similar pattern was noted for ER visits and hospitalizations, for which disease activity, damage, and glucocorticoid dose were significant predictors and not QOC.
Conclusion: High QOC at baseline and the number of years with high QOC are not associated with MCID improvement in SF-36 scores and nonroutine HCU on follow-up. High QOC, as determined by currently defined criteria, serves as a surrogate of greater disease activity, morbidity, and nonroutine HCU.
© 2022 American College of Rheumatology.
Comment in
-
Assessing Systemic Lupus Erythematosus Care: Myopic Evaluations and the Elephant in the Room.Arthritis Care Res (Hoboken). 2023 Jun;75(6):1194-1195. doi: 10.1002/acr.25079. Epub 2023 Feb 1. Arthritis Care Res (Hoboken). 2023. PMID: 36576028 No abstract available.
References
REFERENCES
-
- Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 2017;56:1945-61.
-
- Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016;12:605-20.
-
- Strand V, Gladman D, Isenberg D, et al. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus 2000;9:322-7.
-
- Alarcón GS, McGwin G Jr, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII. Predictors of early mortality in the LUMINA cohort. Arthritis Rheum 2001;45:191-202.
-
- Cook RJ, Gladman DD, Pericak D, et al. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol 2000;27:1892-5.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical